Revolve Wealth Partners LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Revolve Wealth Partners LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,679 shares of the biopharmaceutical company’s stock after purchasing an additional 1,461 shares during the period. Revolve Wealth Partners LLC’s holdings in Pfizer were worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Wealth Alliance Advisory Group LLC raised its holdings in shares of Pfizer by 90.0% during the third quarter. Wealth Alliance Advisory Group LLC now owns 32,735 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 15,507 shares during the last quarter. Waypoint Capital Advisors LLC raised its holdings in shares of Pfizer by 5.5% during the third quarter. Waypoint Capital Advisors LLC now owns 8,980 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 468 shares during the last quarter. Chicago Capital LLC raised its holdings in shares of Pfizer by 0.9% during the third quarter. Chicago Capital LLC now owns 75,895 shares of the biopharmaceutical company’s stock worth $2,196,000 after purchasing an additional 698 shares during the last quarter. Everett Harris & Co. CA raised its holdings in shares of Pfizer by 21.7% during the third quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock worth $6,319,000 after purchasing an additional 38,870 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC increased its holdings in Pfizer by 16.9% in the third quarter. Key Client Fiduciary Advisors LLC now owns 28,710 shares of the biopharmaceutical company’s stock valued at $831,000 after buying an additional 4,156 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday. They issued a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Stock Performance

PFE opened at $29.22 on Friday. The firm has a market capitalization of $165.58 billion, a PE ratio of -487.00, a PEG ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The firm’s 50-day moving average price is $29.07 and its 200 day moving average price is $28.44. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.75%. Pfizer’s payout ratio is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.